Quotient Sciences Completes Qualification of GastroPlus® PBPK Modeling Software
Quotient Sciences’ Modeling and Simulation (M&S) team has recently completed qualification of GastroPlus, the software they use for physiologically based pharmacokinetic (PBPK) modeling. This 2-year project reflects Quotient Sciences’ commitment to conducting high-quality modeling work with regard to data integrity.
Quotient Sciences Expands UK Facilities to Support the Delivery of Translational Pharmaceutics® Programs
Quotient Sciences, a drug development and manufacturing accelerator, has completed major investments and expansions at its Nottingham, UK and Reading, UK, facilities to support the delivery of fully integrated drug development programs through the Company’s flagship platform, Translational Pharmaceutics®.
Gareth Jenkins Contributes to Chemistry Today Panel Discussion on Flow Chemistry
Gareth Jenkins, VP Science and Technology, Candidate Development Services at Quotient Sciences, Contributes to Chemistry Today Panel Discussion on Flow Chemistry. Read it here.
Ensysce Biosciences and Quotient Sciences Announce a Partnership on the Development and Clinical Testing of Ensysce’s PF614-MPAR, a Novel Opioid Designed to Prevent Abuse and Overdose
Partnership further expedites Ensysce’s development pipeline of PF614-MPAR, a novel opioid combination product for the potential treatment of chronic pain that is designed to prevent both abuse and overdose.
Andy Lewis in Drug Development & Delivery: Alternative Strategies for Development of Modified-Release Dosage Forms
Andy Lewis, Vice President, Pharmaceutical Sciences, has written an article for Drug Development & Delivery entitled, "Alternative Strategies for Development of Modified-Release Dosage Forms"
Quality Assurance & Compliance: Addressing and Overcoming the Ever-evolving Challenges in Drug Development and Manufacturing
PharmaTech Outlook Interview with Kimberly Paris, SVP & Chief compliance officer at Quotient Sciences: "Addressing and Overcoming the Ever-evolving Challenges in development"